PLOD Family: A Novel Biomarker for Prognosis and Personalized Treatment in Soft Tissue Sarcoma.
Siming GongNikolas SchopowYingjuan DuanChangwu WuSonja KallendruschGeorg OsterhoffPublished in: Genes (2022)
Despite various treatment attempts, the heterogenous group of soft tissue sarcomata (STS) with more than 100 subtypes still shows poor outcomes. Therefore, effective biomarkers for prognosis prediction and personalized treatment are of high importance. The Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase (PLOD) gene family, which is related to multiple cancer entities, consists of three members which encode important enzymes for the formation of connective tissue. The relation to STS, however, has not yet been explored. In this study, data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases were used to analyze the role of PLOD1-3 in STS. It was found that an overexpression of PLOD family members correlates with poor prognosis, which might be due to an increased infiltration of immune-related cells in the tumor microenvironment. In STS, the expression of PLOD genes could be a novel biomarker for prognosis and a personalized, more aggressive treatment in these patients.
Keyphrases
- poor prognosis
- long non coding rna
- squamous cell carcinoma
- cell proliferation
- papillary thyroid
- combination therapy
- oxidative stress
- dna methylation
- type diabetes
- newly diagnosed
- induced apoptosis
- lymph node metastasis
- cell death
- prognostic factors
- deep learning
- skeletal muscle
- endoplasmic reticulum stress
- patient reported